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Abstract 
Non-coding RNAs are crucial regulators for a vast array of cellular processes and 
have been implicated in human disease. These biological processes represent a 
hitherto untapped resource in our fight against disease. In this work we identify small 
molecule inhibitors of a non-coding RNA uridylylation pathway. The TUTase family 
of enzymes is important for modulating non-coding RNA pathways in both human 
cancer and pathogen systems. We demonstrate that this new class of drug target can 
be accessed with traditional drug discovery techniques. Using the Trypanosoma 
brucei TUTase, RET1, we identify TUTase inhibitors and lay the groundwork for the 
use of this new target class as a therapeutic opportunity for the under-served disease 
area of African Trypanosomiasis. In a broader sense this work demonstrates the 
therapeutic potential for targeting RNA post-transcriptional modifications with small 
molecules in human disease. 
Key words 
TUTase, RET1, RNA modifications, uridylylation, non-coding RNA, trypanosome, 
drug-discovery, African Trypanosomiasis, post-transcriptional modification. 
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Introduction  
RNA plays a vital role in multiple cellular processes, and is involved in many disease 
states, yet drugs that directly target RNA are rare.
1,2
 Interest in how this rich source of 
potential drug targets can be can be tapped continues to grow. In humans, messenger 
RNA (mRNA) is a minor component of total cellular RNA and accounts for less than 
5% of the transcribed genome. Instead, the transcriptome is overwhelmingly 
populated with a complex mixture of non-coding RNAs (ncRNAs) responsible for a 
diverse array of regulatory processes. Such ncRNAs are emerging targets in human 
disease, such as cancer, or for the treatment of parasites, such as the trypanosomes, 
which rely on unique ncRNA machinery for survival.  
One of the principal challenges of targeting a particular RNA with a small molecule 
drug is the lack of well-defined secondary and tertiary structures. A key requirement 
for a small molecule ligand to achieve good potency is a well-defined fit in a binding 
pocket, allowing for multiple interactions to be made between the drug and its target. 
RNA adopts many transient conformations that are generally short-lived and rarely 
fold to generate the cavities that are characteristic of the active sites of many 
druggable enzymes. Thus, a promising strategy to sidestep this difficulty would be to 
target upstream of the RNA transcript by inhibiting proteins that themselves modify 
and regulate RNA. 
To date, drugs that act either directly on ncRNA or upstream via RNA-modifying 
enzymes are few in number and unselective. For example 5-azacytidine inhibits the 
cytosine methylation of both DNA and RNA.
3
 Similarly, enoxacin has been shown to 
act on TRBP protein to inhibit microRNA (miRNA) biogenesis in addition to its 
originally identified mode of action, the inhibition of topoisomerase II.
4
 No small 
molecule therapies specifically targeting non-coding RNAs yet reached the clinic.
5
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One potential class of targets in this field is the RNA terminal uridylyl transferase 
(TUTase) family, which is comprised of enzymes that modulate the function of target 
RNA by the sequential addition of uridines to the 3’ terminus.6 The effects of these 
modifications are system dependent, and can mark a substrate for degradation, act as 
an activation step or prevent downstream processing.
7
 TUTase family enzymes have 
been shown to act on both coding and non-coding RNA.
7
 Crystal structures of 
uridylyl transferases reveal a classically druggable active site and make them 
attractive targets for small molecule therapy.
8
 There are both endogenous and 
exogenous examples of RNA uridylyl transferases relevant in human disease, for 
example, human TUT4, which controls the stability of the Let-7 family of miRNAs 
and has been linked to some forms of cancer.
9.10
 Complementary to this work, the first 
TUT4 inhibitors have been recently reported in this journal.
11
 The trypanosome 
TUTase, RET1, has multiple essential roles for the parasite’s survival in a host, 
including the uridylylation of long non-coding guide RNAs (gRNAs).
12
 Infection of 
human hosts by trypanosomes is responsible for several illnesses including Human 
African Trypanosomiasis (sleeping sickness) and Chagas disease which cause 
devastation in the developing world. Current therapies are inadequate and can be 
fatal.
13
 Previously, RNAi experiments have shown that RET1 expression is essential 
for T. brucei viability. In the absence of RET1, trypanosomes are unable to employ 
their unique RNA editing mechanism which is dependent on the efficient 
polyuridylation of gRNA by the enzyme. The resultant failure in RNA regulation 
results in complete arrest in cell division followed by massive parasitic cell death.
12
 
The lifecycle of T. brucei  is complex with many developmental transitions. Two 
developmental forms can be grown in culture and are experimentally accessible, 
the mammalian bloodstream form and the procyclic form from the tsetse fly 
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midgut. The two forms respond differently to chemical treatments. The 
bloodstream form is clearly of most interest and relevant for the treatment of 
human disease.  Previously published results have demonstrated that RET1 is 
essential for the viability of T. brucei in its procyclic form.12 Its importance in the 
bloodstream form is also supported by data from a whole genome RNAi screen 
and our own work (see supplementary information). 14,15 
RET1 is therefore a particularly relevant target in this disease context. In the present 
study, we develop a high-throughput assay that identifies inhibitors of uridylylation 
activity. We apply this methodology in a proof of concept screen using RET1 to 
demonstrate that TUTases represent a tractable target for drug discovery.   
Results 
Detection of RET1 driven uridylylation of RNA 
In order to develop and use an assay suitable for HTS screening for inhibitors of 
RET1 from T. brucei (Kret1, C9ZSY2_Tb927.7.3950), we first required a robust, 
practical assay system with which we could detect and optimise enzyme activity. 
Previously reported detection of TUTase activity was achieved by measuring the 
increased length of RNA as the enzyme adds successive uridines. This was 
accomplished by radioactive labelling of the nucleotide substrate and quantification of 
the higher molecular weight products on a denaturing agarose gel.
16,17
 The use of 
radioactivity in such assays has historically been driven by the need to identify 
potentially very low quantities of a single substrate from a mixed population of RNA 
derived from a biological sample. The use of purified RNA in vitro overcomes such 
challenges. Thus, to improve throughput we optimised a non-radioactive, gel-based 
protocol using Sybr Gold staining for visualisation of RET1 activity at RNA 
concentrations similar to those used in radioactive experiments.
 16,17
 This simple but 
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important development greatly increased the ease with which we could optimise HTS 
conditions and also provided an orthogonal, gel-based assay to verify hits eventually 
resulting from our screen.  
Full-length RET1 protein (975aa) was expressed in E. coli as an N-terminal 
GST-tagged fusion protein and purified on glutathione sepharose beads as described 
in the Supplementary Information (gel provided in supplementary Fig. S1 & Fig. S2). 
Starting from the conditions reported by Aphasizheva and Aphasizhev (2010) the 
uridylylation reaction was optimized to meet our screening requirements of a 
medium-throughput robust assay and analysed by gel electrophoresis.
17
 The RNA 
substrate is elongated from 24 to approximately 150 bases via RET1 catalyzed 
uridylation (Fig. 1 see Experimental Section for detailed assay protocol). We used 
negative controls to validate this assay, including replacement of RET1 on glutathione 
sepharose beads with glutathione sepharose beads pre-incubated with lysed E. coli 
cells, beads purified with un-induced E. coli extract and a GST tagged N-terminus 
truncation of RET1 (300aa), which does not contain the enzyme active site. 
Development of a high-throughput assay for inhibitors of RET1 activity 
In order to screen a large panel of molecules, we developed a solution based high-
throughput assay to monitor the activity of RET1. As RET1 catalyzes the ligation of 
terminal uridyl groups to the 3’ end of a target ncRNA, the enzyme consumes UTP 
and produces pyrophosphate (PPi) as a by-product. Thus we quantified the production 
of PPi to measure RET1 activity over time. Whilst luciferase coupled PPi detection 
assays of this nature have previously been used to monitor phosphotransferase and 
other enzyme activities, their use in monitoring the post-translational modification of 
nucleic acids is recent, as discussed in the contemporary study on TUT4.
11
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An assay coupling the RET1-catalysed RNA uridylylation with commercially 
available PPiLight
TM
 reagents (Lonza) was developed. During the “reaction” step 
(Fig. 2), poly-U tailing of RNA proceeds with the consumption of UTP and 
production of PPi. During subsequent “conversion” PPi is used to form ATP by 
pyruvate phosphate dikinase (PPKD) within the assay medium. Finally, “detection” is 
facilitated by an ATP-driven luciferase bioluminescent readout. Thus, light output is 
proportional to PPi concentration and hence RET1 activity. Using the gel-based assay 
described above, we were able to determine optimal assay conditions compatible with 
“reaction,” “conversion” and “detection” stages of the reaction and also maintained 
RET1 activity.  
In order to identify substrate-competitive inhibitors, we optimised assay 
conditions at the Km of both RNA and UTP. At these concentrations there is an 
optimal window for competitive inhibition to be observed. Measured Km values for 
RNA substrate (25 nM) and UTP (50 M), were consistent with those previously 
reported.
18
 
Finally, we miniaturized the assay volume, and simplified the liquid dispense 
steps to make them amenable to automated dispensing (see Experimental Section for 
detailed assay protocol). As a result, a robust and reliable assay for the detection of 
RET-1 activity in both 384 and 1536 well format was developed. In order to quantify 
the statistical power of the high-throughput formats, we calculated the Z’ factor for 
our assay. A value above 0.5 indicates that more than 12 standard deviations separate 
the positive and negative controls. In calibration runs for the 384-well format, with 
heat inactivated protein providing the positive inhibition control, the signal-to-
background ratio was approximately 18 and the Z’ factor was 0.77, indicating a 
reproducible and robust screen.  
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Counter-screen to identify false positives 
During screening, false positives could potentially arise from inhibition of the 
conversion or detection steps in this assay. To address this we designed a parallel 
counter-screen assay in which direct addition of PPi replaced the RET1 reaction step. 
Compounds that decreased the luminescence signal this assay would indicate 
inhibition of the “conversion” or “detection” steps rather than direct inhibition of 
RET1. Any compounds giving rise to a luminescence response of similar magnitude 
in both the RET1 screen and the PPi counter screen were likely to be acting 
downstream of RET1. Such compounds were deemed not to be bona fide RET-1 
inhibitors, and were discarded as false positives.  
Identification of small molecule inhibitors of RET1 uridylylation activity 
We used the developed HTS protocol to screen a pilot library of 3,000 compounds 
with the intention to generalize the use of this assay in the screening of TUTases. 
Using RET1 we had three aims; first to identify areas of chemical space in which to 
focus the future search for inhibitors, secondly to investigate the potential for a 
fragment based screening approach in this area and thirdly to identify the first 
inhibitors of this class of enzyme, potentially for use as tool compounds for the 
further investigation of the effects of RET1 inhibition. The compound source was a 
curated NCGC FDA Pharmacology library of previously approved drugs. This 
screening deck was chosen because the compounds are well characterised and have 
been previously used in vivo. This is an attractive strategy where access to ADMET 
assays is limited and where use of compounds with a previously established in vivo 
profile can facilitate and accelerate future cell based or in vivo work.  
Compounds were initially screened at two concentrations from DMSO stock 
in 1536 well format. The shortlist of hits was generated by visual inspection of the 
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data based on overall potency and chemical tractability. False positives were 
identified and discarded using the counter-screen described above. Subsequent to 
primary screen and counter screening, 30 compounds were selected for follow-up, 
representing an acceptable hit rate of 1%. These hits were progressed to the next 
validation step. 
Validation of active compounds 
To appropriately identify the inhibitors that function directly on RET1 uridylylation, 
we screened the 30 short-listed hits in the orthogonal gel-based assay described 
above. This assay allowed for qualitative verification of the inhibitory activity of the 
hits from the luciferase assay and classification of compounds as inactive, moderate 
or strong inhibitors (Table 1).  
Representative gels for compounds 1, 2 and 8 (Fig. 3), demonstrate a clear reduction 
in RNA elongation. Of the 30 putative inhibitors, 11 showed moderate or strong 
activity (see Supplementary Fig. S3 for complete gels). These 11 compounds were 
again cycled through the original screening assay, this time in lower-throughput (384-
well) format and over a wide dose-range in order to determine the IC50s of inhibition. 
The ranking of IC50 values for these compounds was in agreement with their 
qualitative assessment by gel-based assay giving further confidence in these two 
complementary assays (Table 1). 
As is to be expected from a pilot screen of this size, the potency of these hits is 
unlikely to be sufficient for in vivo exploitation. However, they provide useful insight 
for curating libraries in future large scale screens or for the rational design of novel 
inhibitors. Ataciguat (1) and exifone (2) have both been entered into clinical trials for 
unrelated indications.
19,20
 Exifone has also been identified as an anti-protozoan in the 
case of malaria, although a different mode of action is proposed, polypharmacology 
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may contribute to its activity.
21
 Additionally a number of common structural motifs 
were observed including benzyl thiazolidinediones (compounds 3, 4 and 5), a 
structural class which has given rise to successful drugs such as Rosiglitazone,
22
 and 
oestrogen mimetics (6 and 7).
23,24
 Thorough investigation of chemical space around 
these hit clusters could be fruitful in providing more potent hits. This set of RET1 
inhibitors demonstrates that drug-like molecules can indeed target this class of 
enzymes.
 
Additionally, we observed some activity in small fragment-like molecules, for 
example compounds 6 and 8, despite the fact that fragment-like molecules were 
poorly represented in this screening deck. With the wealth of structural information in 
this area derived from a number of TUTase crystal structures, a fragment based 
approach would be suitable for this class of target.
25
 
Although not normally considered drug-like, the aliphatic quaternary amines 
(9, 10, 11) are reported here because compound 9 has been reported to have efficacy 
in the topical treatment of the related pathogen Leishmania.
26
 Of note is the structural 
similarity of these compounds to miltefosine, which was approved by the FDA for 
oral treatment of Leishmaniasis. The specific mode of action for miltefosine is 
unknown (http://www.centerwatch.com/drug-information/fda-approved-
drugs/drug/1311/impavido-miltefosine). Homology between RET1 in T. brucei and 
Leishmania infantum is high in the domains surrounding the active site 
(supplementary Fig. S8) and it is plausible that the RET1 inhibition that we report 
here may indeed contribute to their mode of action.  
Hit compounds are toxic to trypanosomes in culture 
As ataciguat (1) and exifone (2) were among the most potent drug-like hits, and have 
been characterized previously in human subjects, we performed preliminary 
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experiments to evaluate their effect on the trypanosome T. brucei. The lifecycle of T. 
brucei is split into distinct phases depending on whether the host is an insect or 
mammalian. The organism can respond differently to chemical treatments in the 
different forms and the blood form is clearly the most relevant for the treatment of 
human disease. We found that compounds 1 and 2 are toxic to both blood and insect 
forms at concentrations close to their IC50 values (70M and 2M respectively) 
(supplementary Fig. S4). This is an important characteristic of these hit compounds, 
and is consistent with a RET1 driven mode of action. In the case of exifone, its 
potency is sufficient to rule out non-specific cytotoxicity, since it is not toxic to PC12 
cells at concentrations of 10 M.27 A larger scale screen will lead to more potent 
inhibitors for use as tool compounds or hits for a drug discovery programme in this 
area. The chemical space identified in this pilot study can be exploited in such future 
screening efforts. 
Homology model predicts binding modes of ataciguat (1) and exifone (2) 
Several crystal structures of uridylyl transferases have been published in recent years. 
However to date, attempts to crystallise RET1 have been unsuccessful due to its 
preference to form complex interactions with other proteins. Using the wealth of 
information derived from crystal structures of other TUTases, a homology model for 
RET1 was generated.  
We performed manual alignment of RET1 with its close homologue Tb RET2 
(pdb 2B51),
 28
 followed by a homology modelling and energy-scoring protocol. The 
best-scoring models exhibited excellent overlay of all 20 key ligand binding and 
catalytic motif residues in comparison to the Tb RET2 template. Subsequent pair-wise 
clustering of the model ensemble based on these residues revealed limited rotameric 
variability amongst cluster representatives, confirming the quality of the models. The 
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six clusters revealed a limited root-mean square deviation (RMSD) distribution of just 
~1Å, and the central models from the two most populated clusters (covering >95% of 
all models) was chosen for subsequent analysis and docking. Comparison with 
alternative models generated from the crystal structure of the apo and bound states of 
the less closely related TbTUT4 (pdb 2IKF) revealed RMSD distributions of ~2-4 Å, 
confirming TbRET2 as the better starting point. Full details of the generation of the 
homology models and docking protocol can be found in in the Supplementary 
Information.  
We observed two putative binding modes for ataciguat (1). In RET1, both 
binding modes enable similar interactions at either end of the molecule. In 
configuration 1 (Fig. 4a), the terminal chlorine group is in a small hydrophobic 
pocket, Phe296 stacks against the thiophene ring, Tyr524 could potentially stack with 
the central chlorinated ring and the connected sulfonyl oxygen atoms would form 
direct or water mediated H-bonds to nearby charged residues Glu657, Arg664, 
Asp654. These are therefore mostly replacing interactions that would normally be 
stabilizing the uracil base.  Meanwhile, the central carbonyl may interact via water or 
ionic interactions with the catalytic triad aspartate Asp310/Asp312 carboxylates, with 
the sulfonyl oxygen atoms next to the morpholine group interacting with Ser523, and 
the morpholine ring oxygen with Lys509, thus adopting interactions normally 
reserved for the phosphates. In configuration 2 (supplementary Fig. S5), ataciguat (1) 
is rotated by 180 degrees and this pattern is reversed; the morpholine group lies in the 
small hydrophobic pocket and could stack with Phe296, the central benzene could 
stack with Tyr524, the intervening sulfonyl oxygen atoms form direct or water 
mediated H-bonds with Glu657/Arg664/Asp654. The central carbonyl oxygen may 
form H-bonds with nearby catalytic triad aspartates Asp473, Asp310, Asp312, and 
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sulfonyl oxygen atoms adjacent to the thiophene ring would interact with 
Lys505/Lys509/Ser523. Either binding mode predicts a similar interaction, leading to 
a snug fit of the molecule into the elongated RET1 cavity.
29
 The principal reason for 
this is the fact that the binding site is closed off by the conformation of an N-terminal 
domain beta-loop which protrudes into the active site, stabilized by a salt bridge 
between Arg358 and Glu657. 
Modelling of exifone (2) also gave rise to two potential binding modes. In 
configuration 1, exifone is near to the phosphate-binding end of the site (Fig. 4b). 
Ring hydroxyls orient towards Lys509/Ser523 and Asp310/Asp312 which would 
form direct or water-mediated hydrogen bonds with the phosphate 
coordination/catalytic sites. Further along the binding site interactions are limited 
other than a ring hydroxyl H-bond with the sidechain of Asp483. In configuration 2 
(Fig. S6), exifone is nearer to the base-binding site. Some of the previous interactions 
are lost, though ring hydroxyls are still near to the catalytic Asp312 carboxylate. In 
this situation ring hydroxyls are near to base-interaction sites and form direct or 
water-mediated H-bonds to Asp654 and Glu657, the base stacks with Tyr524 and the 
central carbonyl may H-bond to Thr522.  
Selectivity for RET1 inhibitors over the homologue CID1 
One question when investigating a new class of target is whether it is possible 
to obtain sufficient selectivity over related enzymes to achieve a suitable therapeutic 
window. Here we report the first evidence for selectivity of inhibitors between 
members of the TUTase family of enzymes. We adapted our luciferase assay to 
monitor the activity of the commercially available yeast TUTase CID1 (see Online 
Methods in Supplementary Information). Again focusing on the drug-like hit 
compounds that gave complete RET1 inhibition curves, we assessed each for selective 
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inhibition of RET1 over CID1. Representative curves for compounds 1, 2, 10, and 11 
are shown (Fig. 5); and IC50 values, and calculated fold-selectivity for all compounds 
tested is provided (table 2).  
Finally, we used the existing crystal structure of CID1 (pdb 4E80) to build 
hypotheses for the observed selective inhibition of RET1 over CID1.
30
 CID1 residues 
are largely conserved when compared with RET1, and in principle would provide 
similar interactions for compounds such as ataciguat (1). However, the closed NTD 
beta-loop conformation of RET1, which as described above leads to a snug fit of 
inhibitor within its binding cavity, is not present in CID1 despite the conservation of 
the equivalent salt bridge residues (Arg137 and E333 in CID1).  This is demonstrated 
in Fig. 4c, with residues of CID1 labeled and shown in mauve, overlaid on the RET1 
structure shown in cyan in the same orientation as Fig. 4a and 4b. The salt bridge 
observed in RET1 is not formed in CID1, as the guanidinium group of Arg137 in 
CID1 (Arg358 in RET1) is shifted downwards by >10Å, and the carboxylate of 
Glu333 in CID1 (Glu657 in RET1) is shifted out of the binding site by 2Å. The loss 
of the closed binding site would explain the selectivity of Ataciguat for RET1 over 
CID1. There is a histidine residue, His336, in CID1 which is absent in RET1 but 
conserved in mammalian orthologues including all known human TUTases (see Fig. 
S7 for docking model).
30
 This residue increases the local positive electrostatic 
potential near to the equivalent site where the salt bridge in RET1 is present.  We 
postulate that this increased positive electrostatic potential creates an alternative 
“binding site” for Glu333 in CID1, and/or leads to repulsion of Arg137, and is thus 
responsible for destabilization of an otherwise possible Arg137-Glu333 salt bridge 
(Arg358-Glu657 in RET1), causing loss of the closed binding site, and giving rise to 
the observed selectivity of the inhibitors for RET1 over CID1 (Fig. 4c).  
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Conclusions 
Non-coding RNAs remain a little-explored area in drug discovery. The enzymatic 
machinery responsible for the post-translational modification and control of ncRNAs 
presents an enticing hub to exploit post translational modifications as drug targets. 
The TUTase family of enzymes is an integral part of multiple non-coding RNA 
regulatory pathways. In this study we have demonstrated the suitability of this class of 
enzymes as a druggable target. Using RET1 as an example we have developed a 
tractable route for the identification of tool compounds and drug-like inhibitors of 
TUTases, demonstrating one of the first effective and achievable means of 
manipulating disease-relevant regulatory RNAs therapeutically. 
Employing the screening protocol reported in this study, we identified the first 
inhibitors of RET1 from a library of 3,000 small molecules. Hit compounds included 
drug- and fragment-like molecules. We were also able to demonstrate cross-species 
selectivity between TUTase homologues. Using a homology model of RET1, putative 
binding modes were solved for the primary hit compounds. Importantly, this model 
was in agreement with our experimental results and rationalized the selectivity we 
observed over a related RNA processing enzyme. These results will help to inform 
further investigations to identify inhibitors with improved potency against RET1 that 
have the potential to provide a much needed new treatment for African 
trypanosomiasis. 
Experimental Section 
Gel based assay 
Individual reactions were made up in 0.2 ml PCR tubes (Peqlab 820264-A). RET1 
enzyme (see SI text) was added (0.05 l, 0.2 mg ml-1), UTP (Thermo Scientific 
R0471 100 mM) was added to a final concentration of 50 M. RNA substrate (see SI 
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text) was added to a final concentration of 200 nM. Inhibitors were added as required 
(0.5 l in DMSO) to a final concentration of 50 M. When no inhibitor was included 
5 % (vol/vol) DMSO was added as control. The volume was made up to 10 l in 
buffer D (Tris pH 7.5 10 mM, KCl 200 mM, DTT 1 mM, EDTA 0.5 mM MgCl2 3.2 
mM) and the reaction was incubated for 20 mins at 27 °C, then  inactivated at 65 °C 
for 10 mins. RNA loading dye (10 l, NEB B363A) was added and tubes were heated 
(5 mins at 70 °C), 10 l was loaded onto 15 % TBE urea pre-cast gel (Invitrogen 
EC68852) and run in 1 x TBE buffer for 1.5 h at 130 V. Gels were incubated with 
Sybr Gold nucleic acid stain (Life Technologies S11494) for 20 mins, then imaged on 
an ultraviolet trans-illuminator (BioDoc-It imaging system, UVP). Experiments were 
carried out in duplicate for each inhibitor. 
Luciferase assay 384 well format 
Reactions were made up in in Corning® 384 Well Low Flange White Flat Bottom 
Polystyrene TC-Treated Micro plates (Product #3570). RET1 enzyme was added at 
0.1 l (0.2 mgml-1), UTP (Thermo Scientific R0471 100 mM) and RNA substrate 
final concentrations were equal to their Km: 50 M and 20 nM respectively.
18
 The 
volume was made up to 10 l with buffer 6 (Tris pH 7.5 10 mM, KCl 10 mM, DTT 1 
mM, MgCl2 3.2 mM) and the reaction was incubated 20 mins at 25 °C, then heat 
inactivated at 65 °C for 10 mins. Test compounds were added in 0.5 l of DMSO 
stock solution. The positive control included of 0.5 l of DMSO. After a 10 min 
cooling period, 5 l of each of detection and conversion reagents from PPiLight™ 
Inorganic Pyrophosphate Assay Kit (Lonza, LT07-610) were added. Luminescence 
was read with a Pherastar Plus micro plate reader. IC50 determinations were carried 
out in triplicate using the luciferase assay protocol in a dilution series of 1 mM to 99 
nM. 
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Luciferase assay 1536 well format 
Minor modifications were made to the large-format assay to adapt the protocol into 
high-throughput, 1536-well format. Dispense steps were simplified into three steps. 
First,  RET1 (3 µl, 5 µgml
-1
) in buffer 6 was dispensed into each well using a Bioraptr 
reagent dispenser (Beckman-Coulter). Columns 1 and 4 were reserved for negative 
controls and received buffer only. Second, the compound library and DMSO controls 
were dispensed at indicated concentrations in 23 nL using a Kalypsys 1536-pin tool 
(Wako). Finally, RNA substrate (100 nM), UTP (200 µM) and PPi light reagents were 
dispensed in 1µL on the Bioraptr. The plates were read for luminescence 20 mins 
after dispensing using a ViewLux high-throughput charge-coupled device (CCD) 
imager (Perkin-Elmer). Following this initial read, the reaction was spiked with PPi (1 
µL, final concentration 25 nM). The plate was read again in the same fashion to 
identify no responding wells, which represented off target molecules that inhibited the 
assay.  
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Table 1 Summary of performance of validated RET1 inhibitors. Table provides 
qualitative activity in gel based assay, inhibition of RET1 in PPi assay 384-well 
follow-up (reported either as IC50 or % inhibition at 1mM), and qualitative 
determination of UTP competitive binding. nd = value not determined for this 
substrate. 
ID Structure Gel Assay 
RET1 
IC50 
1 
  
strong 70 µM  
2 
 
strong 2.0 µM 
3 
 
strong 500 µM 
4 
 
medium 7% 
5 
 
weak 5% 
6 
 
medium 12% 
7 
 
strong 8 µM 
8 
 
strong 30% 
9 
 
strong 8 µM 
10 
 
strong 15 µM 
11 
 
strong 5 µM 
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Table 2 Results from RET1 selectivity experiments performed with top validated 
hit compounds demonstrate the specific inhibition of the trypanosomal enzyme 
RET1 over an equivalent yeast TUTase CID1.  
  RET1 Inhibition   CID1 Inhibition   RET1 Selectivity (fold) 
Compound IC50 (µM) 
 
SD 
 
IC50 (µM) 
 
SD 
 
  
1 73 ± 12 
 
4800 ± 1700 
 
66 
2 2.0 ± 0.1 
 
88 ± 19 
 
43 
3 500 ± 50 
 
1000 ± 100 
 
2 
7 8.3 ± 0.7 
 
68 ± 1.6 
 
8 
10 15 ± 3.1 
 
270 ± 170 
 
17 
11 4.5 ± 0.8   110 ± 56   24 
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Figure 1 Gel based assay for RET1 activity. RET1 catalyzes the addition of terminal 
uridines resulting in a poly-U RNA product of approximately 150 bases. In the 
absence of RET1, the 24 base RNA target remains unmodified. 
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Figure 2 Schematic for the luciferase coupled HTS assay to detect RET1 activity 
(PPKD – pyruvate phosphate dikinase). 
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Figure 3 Verification of RET1 inhibitors at 50 µM by gel based assay. Lanes from left 
to right: Positive control, RET1 is active in assay buffer conditions (5% DMSO) and 
polyuridylates target RNA producing high molecular weight products; Negative 
control, in the absence of RET1 RNA is not elongated; Compounds 1, 2, and 8 
effectively inhibit the ability of RET1 to uridylate RNA. 
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Figure 4 Putative binding modes predicted using the RET1 homology model. a) 
Ataciguat (1) and b) Exifone (2) docked in the RET1 apo binding site showing 
the most populated cluster. In a) and b), the protein fold is shown in cartoons 
representation, colored by secondary structure (beta-sheet in yellow, alpha-helix 
in purple, loops in cyan). The extensive N-terminal domain beta-loop containing 
the Arg358-Glu657 salt bridge (labelled) helps to create a snug binding site for 
inhibitor. c) Overlay of RET1 homology model (cyan, with sidechains in CPK 
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format) and CID1 crystal structure (all mauve). The residues of CID1 crystal 
structure are labelled, whilst those of the RET1 homology model are unlabelled 
but are shown in the same orientation as in a) and b).  The presence of His336 in 
CID1 increases the electrostatic potential at the top of the binding site, leading to 
separation of Glu333 and Arg137 (residues corresponding to those that form the 
Arg358-Glu657 salt bridge in RET1) leading to a more open binding site in CID1. 
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Figure 5 Representative curves showing RET1 selectivity of short-listed hit 
compounds. Compounds exhibited varying degrees of selectivity for inhibiton of 
RET1 (black curves) over the yeast TUTase CID1 (blue curves).  
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